Advancing Nucleic Acid Therapeutics: Certest Pharma’s Development of Ionizable Lipids, LNP Platforms, and Targeted Delivery Systems.

Certest is a biotechnology company specializing in RNA and oligonucleotide therapeutics, offering end-to-end solutions from early discovery through to preclinical development and IND submission. The company’s key innovation lies in its library of over 1,500 proprietary ionizable lipids, which enable highly efficient and targeted delivery of nucleic acids. These lipids outperform current market standards and are used in both thermostable LNP formulations and advanced targeting systems.

Certest develops custom delivery platforms that include both passive and active targeting approaches, such as ligand- and peptide-conjugated LNPs and oligonucleotides. These technologies allow precise delivery to specific organs or cell types and have shown remarkable results in preclinical models.

In addition to delivery technologies, Certest also provides synthesis and optimization of mRNA, saRNA, circRNA, and siRNA, with a focus on codon optimization and UTR design for enhanced protein expression. The company supports clients with analytical development, formulation, scale-up, and regulatory documentation, operating from over 3,000 square meters of lab space with a team of more than 75 professionals.

This presentation highlights Certest’s capabilities across its proprietary technologies, service offerings, and partnership models, positioning the company as a comprehensive and flexible partner for RNA-based therapeutic development.